A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects
Phase 4
Completed
- Conditions
- Healthy Volunteers
- Registration Number
- NCT00251030
- Lead Sponsor
- Pfizer
- Brief Summary
To estimate the effects of omeprazole on the pharmacokinetics of nelfinavir in healthy subjects
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Healthy male or female subjects between the ages of 18 and 55 years.
Read More
Exclusion Criteria
- Subjects with hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method To estimate the effects of multiple doses of omeprazole on the steady-state pharmacokinetics of nelfinavir and M8 in healthy subjects
- Secondary Outcome Measures
Name Time Method To evaluate the safety and tolerability of the 625 mg formulation of nelfinavir when administered alone and with omeprazole
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Kalamazoo, Michigan, United States